FierceBiotechQwen · 实盘不做把握 9/10不做原因:消息已过时
北京时间·🕒 发布 22:35:00(美东 10:35)时区推断·⟳ 抓取 23:04:04·⚡ 决策 09-04 23:07:06 +3m02s·53.0 天前
Menarini与甘李药业签署博凡格鲁肽欧洲授权协议（€6200万首付+最高€6.64亿里程碑）——该交易已于8月10日公告并充分定价
该交易已于2026年8月10-11日通过巨潮资讯正式公告（编号2026-062），甘李药业当日涨停、次日续涨3.67%，市值达461亿元，多家券商发布研报。FierceBiotech 9月4日报道是英文媒体对同一事件的延迟覆盖，所有条款（€6200万首付、€6.64亿里程碑、39国、双位数royalty）与原始公告完全一致，无任何新增事实。股价已从公告后高点回落约13%至70.10元，事件已充分消化。
📄 原文FierceBiotech↗ 原文
Menarini signs $771M deal to take Gan & Lee GLP-1 to European market
Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 m…
不做 甘李药业（603087.SH）
该交易已于2026年8月10-11日通过巨潮正式公告并引发涨停+续涨，股价已从高点回落13%。FierceBiotech 9月4日报道为英文媒体延迟覆盖，条款与原始公告完全一致，无任何新增事实（无金额修正、无新适应症、无监管进展）。事件已充分定价，无剩余edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Menarini与甘李药业的博凡格鲁肽欧洲授权协议（€7.26亿潜在总额）于2026年8月10-11日通过巨潮资讯正式公告，甘李药业当日涨停、次日续涨。FierceBiotech 9月4日报道为英文媒体延迟覆盖同一交易，条款完全一致，无新增金额、适应症扩展或监管进展。股价已从高点回落13%，事件已充分定价，无剩余交易edge。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-09-04 · 影响 invalidates
KB中未找到8月11日公告后任何关于该交易的新增事实、进展或条款变更；9月4日FierceBiotech文章无新信息
检索:甘李药业 博凡格鲁肽 Menarini 新增事实 进展 2026年9月
先例如何影响了这次决策
对本次决策的影响:事件已确认为3周前已公告并充分定价的交易的延迟英文报道，无需先例校准
方向:无需先例——事件已确认为旧闻重复报道
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 7 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 778 ms
{"result": "search_processed_events:agent query=`gan lee pharmaceuticals licensing europe | menarini gan lee bofanglutide glp-1 deal | 甘李药业 博凡格鲁肽 欧洲 授权`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、7251 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - fetch_decision_experience 成功 stock_tools HTTP · 105 ms
{ - stock_quote 成功 stock_tools HTTP · 346 ms
{ - kb_search 成功 stock_tools HTTP · 6,108 ms
{ - search_case_library 成功 stock_tools HTTP · 146 ms
{"result": "search_case_library「603087.SH」—— 与这些标的相关的自家决策案例(本页 9 条,该标的全历史相关记录共 9 条；ENTER 只按该标的自己的腿统计):\n◆ 603087.SH：相关历史决策 9 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 9 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-08-30 UTC 不做 · 事件:JW Pharmaceutical - kb_fetch_document 成功 stock_tools HTTP · 209 ms
{ - kb_fetch_document 成功 stock_tools HTTP · 291 ms
{
原文全文
展开原文 · 2,235 字
Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million) up front to collaborate on the registration and commercialization of Gan & Lee’s GLP-1 bofanglutide.
Gan & Lee will also be eligible to receive milestone payments of up to €664 million ($771 million), as well as double-digit royalties on sales, according to a release.
Menarini will take over regulatory submissions and commercialization in a total of 39 countries, including the 27 European Union countries, the U.K., Switzerland, Norway, Iceland, Liechtenstein and the Balkan countries.
“This partnership establishes a pivotal pathway for bofanglutide’s entry into the European market and marks another milestone in Gan & Lee’s transformation—from a leader in insulin to a global innovator in metabolic disease,” Wei Chen, Ph.D., chairman and CEO of Gan & Lee, said in a Sept. 3 statement.
Bofanglutide is administered subcutaneously once every two weeks, requiring half the administration frequency of once-weekly GLP-1s. It completed a phase 3 study in China and a phase 2 study in the U.S. in patients who were overweight, obese or had Type 2 diabetes. Both studies met their primary endpoints, demonstrating weight loss and tolerability consistent with other GLP-1s. Gan & Lee plans to initiate a global phase 3 trial to support registration in Europe and other highly regulated markets.
The deal comes two years after Gan & Lee announced that bofanglutide outperformed Novo Nordisk’s Ozempic (semaglutide) in reducing glycated hemoglobin (HbA1c) and body weight in a phase 2 trial of patients with Type 2 diabetes.
While the partnership will extend Gan & Lee’s geographical reach, it is also designed to expand Menarini’s presence in the metabolic space and in innovative primary and specialty care sectors.
Elcin Barker Ergun, group CEO of Menarini, noted that the deal will leverage Menarini’s capabilities in the region. “Clinical study results for bofanglutide so far have demonstrated weight reduction, secondary metabolic benefits and a safety profile consistent with expectations for this class, while its once-every-two-weeks dosing regimen offers an opportunity for differentiation,” he said.
Gan & Lee will also be eligible to receive milestone payments of up to €664 million ($771 million), as well as double-digit royalties on sales, according to a release.
Menarini will take over regulatory submissions and commercialization in a total of 39 countries, including the 27 European Union countries, the U.K., Switzerland, Norway, Iceland, Liechtenstein and the Balkan countries.
“This partnership establishes a pivotal pathway for bofanglutide’s entry into the European market and marks another milestone in Gan & Lee’s transformation—from a leader in insulin to a global innovator in metabolic disease,” Wei Chen, Ph.D., chairman and CEO of Gan & Lee, said in a Sept. 3 statement.
Bofanglutide is administered subcutaneously once every two weeks, requiring half the administration frequency of once-weekly GLP-1s. It completed a phase 3 study in China and a phase 2 study in the U.S. in patients who were overweight, obese or had Type 2 diabetes. Both studies met their primary endpoints, demonstrating weight loss and tolerability consistent with other GLP-1s. Gan & Lee plans to initiate a global phase 3 trial to support registration in Europe and other highly regulated markets.
The deal comes two years after Gan & Lee announced that bofanglutide outperformed Novo Nordisk’s Ozempic (semaglutide) in reducing glycated hemoglobin (HbA1c) and body weight in a phase 2 trial of patients with Type 2 diabetes.
While the partnership will extend Gan & Lee’s geographical reach, it is also designed to expand Menarini’s presence in the metabolic space and in innovative primary and specialty care sectors.
Elcin Barker Ergun, group CEO of Menarini, noted that the deal will leverage Menarini’s capabilities in the region. “Clinical study results for bofanglutide so far have demonstrated weight reduction, secondary metabolic benefits and a safety profile consistent with expectations for this class, while its once-every-two-weeks dosing regimen offers an opportunity for differentiation,” he said.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。